Takeda Told By U.S. FDA To Add Warning To Actos Label
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical took a major hit when the U.S. FDA said the company would have to warn prospective one-year users of the diabetes drug Actos (pioglitazone) that it could cause an increased risk of bladder cancer